NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
AbstractMultiple myeloma with clonal plasma expansion in bone marrow is the second most common hematologic malignancy in the world. Though the improvement of outcomes from the achievement of novel agents in recent decades, the disease progresses and leads to death eventually due to the elusive nature of myeloma cells and resistance mechanisms to therapeutic agents. In addition to the molecular and genetic basis of resistance pathomechanisms, the bone marrow microenvironment also contributes to disease progression and confers drug resistance in myeloma cells. In this review, we focus on the current state of the literature in terms of critical bone marrow microenvironment components, including soluble factors, cell adhesion mechanisms, and other cellular components. Transcriptional factor nuclear factor erythroid-derived-2-like 2 (NRF2), a central regulator for anti-oxidative stresses and detoxification, is implicated in chemoresistance in several cancers. The functional roles of NRF2 in myeloid-derived suppressor cells and multiple myeloma cells, and the potential of targeting NRF2 for overcoming microenvironment-mediated drug resistance in multiple myeloma are also discussed. View Full-Text
Share & Cite This Article
Yen, C.-H.; Hsiao, H.-H. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma. Int. J. Mol. Sci. 2018, 19, 3503.
Yen C-H, Hsiao H-H. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma. International Journal of Molecular Sciences. 2018; 19(11):3503.Chicago/Turabian Style
Yen, Chia-Hung; Hsiao, Hui-Hua. 2018. "NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma." Int. J. Mol. Sci. 19, no. 11: 3503.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.